Viatris Sees Vision Drugs as Key to Growth and Commits $750M to Two M&A Deals

ūüí° This post was automatically imported from MedCity News. You can find the original article here.
Author: Frank Vinluan

Two years after the close of the merger that formed Viatris, the company is acquiring Oyster Point Pharma and Famy Life Sciences to expand its scope in ophthalmology, one of three therapeutic areas it is now focusing on for revenue growth.

The News Aggregator will pull the latest articles and news from around the internet to present them in one place for you to easily keep up to date on all things related to Medical Informatics.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

Welcome to MediFormatica. The site is still under construction so there are some rough edges here and there, but I'll be adding new and exciting content every day. So enjoy it and come back again for more great stuff.